IN8BIO, Inc.
INAB- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001740279
No open-market purchases or sales by IN8BIO, Inc. insiders were filed in the last 90 days; 21 institutions reported holding it in 13F filings for Q2 2026, worth $5.35M in total; no superinvestor holds it.
Q1 2025 vs. Q4 2024
How the institutions holding IN8BIO, Inc. changed between Q4 2024 and Q1 2025.
All holders in Q1 2025All holders in Q4 2024
| Measure | Q4 2024 | Q1 2025 | Change |
|---|---|---|---|
| Holders | 26 | 28 | +2 |
| Shares | 30.0M | 21.7M | −8.35M (−27.8%) |
| Value | $7.72M | $3.60M | −$4.12M (−53.4%) |
New holders (6)
Institutions that held IN8BIO, Inc. at the end of Q1 2025 but not at the end of Q4 2024.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Chicago Partners Investment Group LLC | 69,301 | $11.4K | 0.00% |
| Two Sigma Securities, LLC | 34,279 | $5.69K | 0.00% |
| Citadel Advisors LLC | 29,450 | $4.89K | 0.00% |
| Susquehanna International Group, LLP | 24,812 | $4.12K | 0.00% |
| Capital Investment Advisory Services, LLC | 17,605 | $2.92K | 0.00% |
| Northwestern Mutual Wealth Management Co | 8,263 | $1.37K | 0.00% |
Sold out (4)
Institutions that held IN8BIO, Inc. at the end of Q4 2024 and filed for Q1 2025 without it.
| Institution | Shares, Q4 2024 | Value, Q4 2024 |
|---|---|---|
| 683 Capital Management, LLC | 750,000 | $192.9K |
| Jane Street Group, LLC | 115,919 | $29.8K |
| Goldman Sachs Group Inc | 10,193 | $2.62K |
| Rock Creek Group, LP | 1 | $0 |